Webinar: mRNA Is Never Naked, Exploring RBP Target Space & Therapeutic Opportunities

2023-11-14

siRNA

mRNA is never caught naked. RNA binding proteins (RBPs), act as vigilant guardians, covering RNA within cells. The role of RBPs is multifaceted, affecting mRNA processing, localization, life-time, and translation, working at steady state or leading to an instantaneous effect on their target mRNA upon stimuli. RBPs constitute an unexplored frontier, specifically implicated in different diseases including cancer, Neurodegeneration, and inflammation. Over the last decade, advancements in this novel target space have brought us to a juncture where the promise of these new therapeutic opportunities is greater than ever. Watch this webinar to gain insights from expert speakers who have made significant advancements in the field of RBPs: Definition of an RBP – domains and functional activity Identification of novel RBPs and RBP-RNA interaction using machine learning Delve into innovative strategies for discovering RBP modulators Register to watch Panelists Dr. Iris Alroy, PhD Anima Biotech | Co-Founder and Chief Scientific Officer Iris Alroy, Ph.D. has over 25 years of experience in drug discovery, preclinical and early clinical development. Dr. Alroy has served as co-founder and CSO of Anima since 2015, supervising drug discovery and pipeline development in the emerging field of mRNA translation regulation. Prior to Anima, she acted as VP of Discovery at Proteologics and Pharmos Corp. and CEO of several startup biotech companies, including Fusimab, Ltd. and ProMining Therapeutics Ltd. Dr. Alroy earned her doctorate in Cell Biology from Cornell University and completed a post-doctoral fellowship at the Weizmann Institute. She has authored more than 20 scientific articles in peer-reviewed journals. Dr. Kristopher W. Brannan, PhD Houston Methodist Research Institute, Weill Cornell Medical College | Assistant Professor Kristopher Brannan is an Assistant Professor and CPRIT Scholar in the Center for RNA Therapeutics and Houston Methodist Cancer Center at the Houston Methodist Research Institute. He received his B.A. degree in molecular, cellular and developmental biology at the University of Colorado Boulder, and his Ph.D. in molecular biology at the University of Colorado School of Medicine. He was a postdoctoral fellow at the University of California San Diego and joined the faculty at the Houston Methodist Research Institute in 2021. His work is focused on RNA-protein interactions that regulate gene expression programs disrupted in cancer and neurological disease.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构